Chronic Rhinosinusitis
3
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
CT
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 program1
300mg/600mg of TQH2722 injectionPhase 21 trial
Active Trials
Airiver MedicalMN - Brooklyn Park
1 program1
Airiver Nasal Drug Coated BalloonPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Chia Tai TianQing Pharmaceutical Group300mg/600mg of TQH2722 injection
AnaptysBioEtokimab
Airiver MedicalAiriver Nasal Drug Coated Balloon
TivicMicrocurrent TENS device
Clinical Trials (4)
Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps
Start: Jul 2024Est. completion: Jun 2026
Phase 2Recruiting
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Start: Nov 2018Est. completion: Oct 2020
Phase 2Completed
Paclitaxel-Coated Nasal Balloon for the Treatment of Recurrent Chronic Rhinosinusitis With or Without Nasal Polyps (FIH)
Start: Jun 2023Est. completion: Dec 2029
Phase 1Active Not Recruiting
Microcurrent Device (TIVIC Health)
Start: Mar 2022Est. completion: Apr 2024
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
4 companies competing in this space